Frailty and Bone Disease

Uses

How it works

Evidence quality

Highlighted claims

• Hospital admission and comorbidity data will be used to derive and externally validate several frailty tools. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• The simplified International Myeloma Working Group frailty scale will use age, Charlson Comorbidity Index, and ECOG performance status to classify patients as frail or non-frail. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Skeletal-related events will be derived from healthcare systems data using ICD-10 and OPCS-4 codes in HES and radiotherapy data. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Frailty classifications will be externally validated against outcomes including overall survival, progression-free survival, and early mortality. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• BLISS will examine myeloma bone disease as an important endpoint that has been difficult to assess in randomised controlled trials. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data